MPWT
BTAI icon

MassMutual Private Wealth & Trust’s BioXcel Therapeutics BTAI Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19
Closed -$838 – 2143
2024
Q1 		$838 Buy
+19
New +$906 ﹤0.01% 1749

Other funds holding BTAI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

MassMutual Private Wealth & Trust's BTAI Position: Q2 2024 in Review

MassMutual Private Wealth & Trust sold out of BioXcel Therapeutics (BTAI) in Q2 2024, closing a stake of 19 shares — an estimated $838 sold.

MassMutual Private Wealth & Trust first reported a position in BTAI in Q1 2024 and held it in 1 quarter. The position peaked at $838 in Q1 2024. 74 funds tracked by Wall St. Rank hold BTAI as of Q2 2024.

  • MassMutual Private Wealth & Trust reported no remaining BioXcel Therapeutics position as of Q2 2024 after selling out during the quarter.
  • MassMutual Private Wealth & Trust sold 19 BioXcel Therapeutics shares in Q2 2024, an estimated $838.
  • MassMutual Private Wealth & Trust first reported a position in BioXcel Therapeutics in Q1 2024 and held it in 1 quarter.
  • MassMutual Private Wealth & Trust's BioXcel Therapeutics position peaked at $838 in Q1 2024.
  • 74 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2024.

Based on MassMutual Private Wealth & Trust's 13F filing for Q2 2024, filed 2 Jul 2024.